Stemline Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering

Stemline Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering

NEW YORK, April 3, 2012 /PRNewswire via COMTEX/ -- Stemline Therapeutics, Inc., a clinical-stage biopharmaceutical company developing oncology therapeutics that target both cancer stem cells (CSCs) and tumor bulk, announced today that it has filed a registration statement with the Securities and Exchange Commission for a proposed initial public offering of its common stock. The offering size and the estimated price range of the offering have not yet been determined. All shares proposed to be included in the offering will be sold by Stemline.

Oppenheimer & Co. Inc. and JMP Securities LLC are acting as joint book-running managers for the offering.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission, but has not yet become effective. These securities may not be sold and offers to buy may not be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, and there shall not be any sale of these securities in any state in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state.

The offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus relating to and describing the terms of this offering may be obtained by contacting Oppenheimer & Co. Inc., Attention: Syndicate Prospectus Department, 85 Broad Street, 26th Floor, New York, NY, 10004, (212) 667-8563, [email protected], or JMP Securities LLC, Attention: Prospectus Department, 600 Montgomery Street, Suite 1100, San Francisco, California 94111, (415) 835-8985.

Stemline Contact:

Mark JacobsonDirector, Corporate DevelopmentStemline Therapeutics, Inc.750 Lexington AvenueSixth FloorNew York, NY 10022Tel: 646-502-2307Email: [email protected]

SOURCE Stemline Therapeutics, Inc.

Suggested Articles

Werewolf is launching with $56 million and an approach that can cut through the toxic effects that have limited certain cancer-killing agents.

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.